Bhubaneswar: India’s indigenous COVID-19 vaccine Covaxin reportedly faced an adverse incident during its Phase I trial back in August. The company claims that it reported the incident within 24 hours.
“The adverse event during Phase I clinical trials in August 2020 was reported to the CDSCO-DCGI, within 24 hours of its occurrence and confirmation,” Bharat Biotech said in a statement on Saturday.
The Hyderabad-based firm is working with ICMR to produce the vaccine which has now received approval for Phase III trials.
The vaccine is being tested at 21 medical institutes in the country, including IMS & SUM Hospital in Bhubaneswar.
“The adverse event was investigated thoroughly, and presented to the CDSCO-DCGI, prior to obtaining permission for Phase II and Phase III clinical trials,” said Bharat Biotech.
Bhubaneswar: Commissionerate Police busted a cyber crime gang and arrested three persons involved in an…
Bengaluru: As if an alleged sex scandal and SIT probe wasn’t enough, Janata Dal (Secular)…
Bhubaneswar: BJP's national president JP Nadda kicked off the party campaign for Lok Sabha and…
New Delhi: Eight days after postponing his two-day trip to India, Elon Musk arrived in Beijing…
Bhubaneswar: With severe heatwave conditions gripping Odisha, maximum temperature shot up to 43 degree Celsius…
Mumbai: Samantha Ruth Prabhu had a special birthday treat for her fans on Sunday, when…
Bhubaneswar: The India Meteorological Department (IMD) has forecast thunderstorm with lightning in 4 districts and…
Bhubaneswar: Biju Janata Dal (BJD) on Sunday moved Odisha’s Chief Electoral Officer (CEO) accusing Bharatiya…